Merck responds to US FDA communiqué regarding leukotriene inhibitors
Wednesday, June 17, 2009 16:00 IST Whitehouse Station, New Jersey
Merck & Co, Inc issued the statement in response to communication from the US Food & Drug Administration (FDA) addressing updated information on leukotriene inhibitors, including Singulair (montelukast sodium).